Aditxt

Aditxt Buyback Yield

The Buyback Yield of Aditxt (ADTX) as of Oct 28, 2026 is 2,666.30 %. In the previous year, Buyback Yield was 825.94 % — a change of 222.82% (higher).

Buyback Yield

2,666.30 %

YoY

222.82%

Last updated:

Buyback Yield of Aditxt is 2025 2,666.30 % . Buyback Yield of Aditxt was 2024 825.94 % . It decreases by 222.82% higher compared to the previous year.

The Aditxt Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
182.81 USD
Jan 1, 2019
136.17 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
5.79 USD
Jan 1, 2023
0.29 USD
Jan 1, 2024
825.94 USD
Jan 1, 2025
2,666.30 USD
The Aditxt Buyback Yield history
YEARBuyback YieldYoY
2,666.30 %+222.82%
825.94 %+285,087.10%
0.29 %-95.00%
5.79 %—
0.00—
0.00-100.00%
136.17 %-25.51%
182.81 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Buyback Yield of Aditxt is 2,666.30 % in 2025.

Buyback Yield of Aditxt changed from 825.94 % to 2,666.30 %, representing a 222.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Buyback Yield Aditxt since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's Aditxt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aditxt

All Key Metrics — Aditxt